Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

Nour Moukalled, MD, Radwan Massoud, BS, MD, Rami Mahfouz, MD, Jean Elcheikh, MD, Ali Bazarbachi, MD PhD

Blood (2018) 132 (Supplement 1): 5445.

https://doi.org/10.1182/blood-2018-99-118893

Published: 2018

Journal Articles

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

Ibraheem H. Motabi, MD, Shahid Iqbal, MD, Syed Ziauddin A. Zaidi, FRCP, FRCPath, MBBS, Belal Albtoosh, BSc, RN, Nawal Faiez Alshehry, MD, Mubarak S. AlGhamdi, MD, Imran Khan Tailor, MD, Syed Altaf, MD

Blood (2018) 132 (Supplement 1): 5181.

https://doi.org/10.1182/blood-2018-99-114037

Published: 2018

Journal Articles

Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review

Ilana Schlam, MD, Samantha Buszek*, MD, James Essell

Blood (2017) 130 (Supplement 1): 5508.

https://doi.org/10.1182/blood.V130.Suppl_1.5508.5508

Published: 2017

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Therapy-Related Acute Lymphoblastic Leukemia/Lymphoma in the Elderly

Kevin C. Miller, BS, Aref Al-Kali, MD, William J. Hogan, MBBCh, Michelle A. Elliott, MD, Kebede H. Begna, MD, Naseema Gangat, MBBS, Mrinal M. Patnaik, MDMBBS, Lisa Sproat, MD MSW, James M. Foran, MD, Mark R. Litzow, MD, Hassan B. Alkhateeb, MD

Blood (2017) 130 (Supplement 1): 5010.

https://doi.org/10.1182/blood.V130.Suppl_1.5010.5010

Published: 2017

Journal Articles

Inflammatory and Autoimmune Manifestations Associated with Lymphoid Neoplasms: A French Multicenter Retrospective Study

Vincent Jachiet, Eric Grignano, Arsène Mekinian, Paul Coppo, MD PhD, Olivier Fain

Blood (2016) 128 (22): 5335.

https://doi.org/10.1182/blood.V128.22.5335.5335

Published: 2016

Journal Articles

Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia

Benoit Brethon, MD, Laetitia Morel, MD, Arnaud Petit, MD PhD, Etienne Lengliné, MD, Aurelie Cuinet, MD, Genevieve Vaudre, Thierry Leblanc, MD, Marie-Dominique Tabone, MD, Guy Leverger, MD, Nicolas Boissel, MD PhD, André Baruchel, MD

Blood (2014) 124 (21): 3723.

https://doi.org/10.1182/blood.V124.21.3723.3723

Published: 2014

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Arati Rao, MD, David A. Rizzieri, MD, Eduardo Vanegas, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4948.

https://doi.org/10.1182/blood.V120.21.4948.4948

Published: 2012

Journal Articles

Incidence of Autoimmunity in Patients (pts) with Low-Risk (LR) Myelodysplastic Syndrome (MDS): 10 Years Follow-up

Ahmed Elkhanany, Curtis A. Hanson, MD, Mrinal Patnaik, Michelle Elliott, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2012) 120 (21): 4931.

https://doi.org/10.1182/blood.V120.21.4931.4931

Published: 2012

Journal Articles

Successful Autologous Peripheral Blood Stem Cell Transplantation In Severe Refractory Dermatomyositis

Francesca Saltarelli, Raffaele D’Amelio, Raffaele Porrini, Giovanni Antonini, Antonella Ferrari, Esmeralda Conte, Francesca Milanetti, Bruno Laganà, Giusy Antolino, Enrico Montefusco

Blood (2011) 118 (21): 4507.

https://doi.org/10.1182/blood.V118.21.4507.4507

Published: 2011

Journal Articles

Efficacy and SAFETY of Dasatinib 50 MG Once Daily DOSE In PATIENTS with CHRONIC PHASE CML WHO Failed IMATINIB

Mohamed A. Yassin, MBBS, MSc, CABM, FACP, Hanadi R. El-Ayoubi, MD, Rami T Kamzoul, DA

Blood (2011) 118 (21): 4440.

https://doi.org/10.1182/blood.V118.21.4440.4440

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Neil Shah, MD, Ph.D., Hagop Kantarjian, MD, Andreas Hochhaus, MD, Jorge E. Cortes, MD, M. Brigid Bradley-Garelik, MD, Chao Zhu, PhD, Michele Baccarani, MD

Blood (2010) 116 (21): 206.

https://doi.org/10.1182/blood.V116.21.206.206

Published: 2010

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Francesc Bosch, MD, PhD, Neus Villamor, Pau Abrisqueta, MD, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD

Blood (2010) 116 (21): 1382.

https://doi.org/10.1182/blood.V116.21.1382.1382

Published: 2010

Journal Articles

Dengue Virus Associated Hemophagocytic Syndrome with Neurogical Manifestations in Children: A Case Report.

Yadira Soler-Rosario, M.D., Nilka J. Barrios, MD, Ricardo Garcia, M.D., Alicia Fernandez-Sein, M.D., Enid Rivera, M.D.

Blood (2009) 114 (22): 4516.

https://doi.org/10.1182/blood.V114.22.4516.4516

Published: 2009

Journal Articles

Severe Rhabdomyolysis and Acute Renal Failure Secondary to Use of All–Trans-Retinoic Acid in a Patient with Acute Promyelocytic Leukemia.

Shenxian Qian, MD, Yaping Xie, Xilian Huang, DaQuan Gao, LiRong Liu, Kuang Chen

Blood (2009) 114 (22): 4138.

https://doi.org/10.1182/blood.V114.22.4138.4138

Published: 2009

Journal Articles

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Robert A. Baiocchi, Lapo Alinari, Thomas S. Lin, Pierluigi Porcu, Jeffrey Jones, Joseph Flynn, William Hicks, Margaret S. Lucas, Lai Wei, Jeffrey S. Johnston, John C. Byrd

Blood (2008) 112 (11): 3053.

https://doi.org/10.1182/blood.V112.11.3053.3053

Published: 2008

NARROW

Imatinib Mesylate Is Safe and Effective in Maintaining Cytogenetic and Molecular Response Achieved with 1 Year Nilotinib First Line in Newly Diagnosed Chronic Myeloid Leukemia: Preliminary Results of a Prospective Clinical Trial

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

Myositis-like Chronic Graft Versus Host Disease: Case Series and Literature Review

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Therapy-Related Acute Lymphoblastic Leukemia/Lymphoma in the Elderly

Inflammatory and Autoimmune Manifestations Associated with Lymphoid Neoplasms: A French Multicenter Retrospective Study

Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Incidence of Autoimmunity in Patients (pts) with Low-Risk (LR) Myelodysplastic Syndrome (MDS): 10 Years Follow-up

Successful Autologous Peripheral Blood Stem Cell Transplantation In Severe Refractory Dermatomyositis

Efficacy and SAFETY of Dasatinib 50 MG Once Daily DOSE In PATIENTS with CHRONIC PHASE CML WHO Failed IMATINIB

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Dengue Virus Associated Hemophagocytic Syndrome with Neurogical Manifestations in Children: A Case Report.

Severe Rhabdomyolysis and Acute Renal Failure Secondary to Use of All–Trans-Retinoic Acid in a Patient with Acute Promyelocytic Leukemia.

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only